Drug intelligence / Profile preview

anti-IL-20RB antibody

Development stage
Preclinical
Lead developer
University of Lille
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
01

Overview

The anti-IL-20RB antibody is a monoclonal antibody that targets the interleukin-20 receptor subunit beta (IL-20RB), a shared component of the heterodimeric receptor complexes for the IL-20 subfamily of cytokines, including IL-19, IL-20, and IL-24. In the context of chronic obstructive pulmonary disease (COPD), chronic exposure to cigarette smoke induces the expression of IL-20RB in the airway epithelium. Signaling through this receptor by IL-20 cytokines has been shown to impair epithelial wound healing and repair processes under stress conditions. By neutralizing IL-20RB, the antibody blocks these inhibitory signals and promotes epithelial cell proliferation, thereby restoring the integrity of the airway epithelial barrier. This therapeutic approach is being explored to address the defective repair mechanisms and chronic inflammation characteristic of COPD and other mucosal inflammatory diseases.

Other names
anti-IL-20Rb antibodyanti-IL20Rb antibodyanti-IL 20Rb antibodyIL-20RB antagonistIL20RB antagonistIL 20RB antagonistanti-IL-20RB mAbanti-IL20RB mAbanti-IL 20RB mAb
02

Targets

IL20RB (Interleukin-20 receptor subunit beta)

Beyond the preview

Go deeper on anti-IL-20RB antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-IL-20RB antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call